Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of rimegepant for migraine prevention in children and adolescents
2024-512382-13-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in migraine and episodic migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Mean change from baseline in monthly migraine days over Weeks 1 to 12. Planned start Oct 2022; status: authorised.
02
Drugs
rimegepant
03
Conditions
migraineepisodic migraine
Beyond the preview
Go deeper on 2024-512382-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512382-13-00.